On the evaluation of drug benefits policy changes with longitudinal claims data: the policy maker's versus the clinician's perspective
- 15 January 2001
- journal article
- research article
- Published by Elsevier in Health Policy
- Vol. 55 (2) , 97-109
- https://doi.org/10.1016/s0168-8510(00)00120-2
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Thrombotic vascular events after change of statinThe Lancet, 1999
- Increased thrombotic vascular events after change of statinThe Lancet, 1998
- National Health Expenditures In 1997: More Slow GrowthHealth Affairs, 1998
- What is Germany's experience on reference based drug pricing and the etiology of adverse health outcomes or substitution?Health Policy, 1998
- Can Medical Savings Accounts for the Nonelderly Reduce Health Care Costs?JAMA, 1996
- Why has Patient Compliance become Important?Clinical Research and Regulatory Affairs, 1994
- A Critical Analysis of Studies of State Drug Reimbursement Policies: Research in Need of DisciplineThe Milbank Quarterly, 1993
- Reducing Bias in Observational Studies Using Subclassification on the Propensity ScoreJournal of the American Statistical Association, 1984